NCT03112603 2025-08-12A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)Incyte CorporationPhase 3 Completed330 enrolled 32 charts 2 FDA